Biofrontera shows robust growth during first six months of 2019
August 27, 2019 02:15 ET
|
Biofrontera AG
Leverkusen, Germany, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ devimistat (CPI-613®) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
January 10, 2019 11:00 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the European Medicines Agency...
EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ devimistat (CPI-613®) for Treatment of Metastatic Pancreatic Cancer
January 10, 2019 08:00 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the European Medicines Agency...
Biofrontera receives FDA approval for upscaling of batch size for Ameluz® production
January 08, 2019 02:02 ET
|
Biofrontera AG
Leverkusen, Germany, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that...
Melinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam)
November 27, 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries
October 01, 2018 08:15 ET
|
Melinta Therapeutics
- Total consideration of up to $265 million (including potential royalties) -- Expands on existing commercial and co-development agreement for Baxdela® (delafloxacin) - NEW HAVEN, Conn. and FLORENCE,...
Melinta Therapeutics Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam)
September 21, 2018 07:37 ET
|
Melinta Therapeutics
Recommended to be approved for treatment of: Complicated intra-abdominal (cIAI) and urinary tract infections (cUTI) -Hospital-acquired pneumonia including ventilator associated pneumonia...
REPEAT- Maricann Group Inc. is Awarded GMP Certification
April 30, 2018 08:00 ET
|
Maricann Group Inc.
TORONTO, April 30, 2018 (GLOBE NEWSWIRE) -- Maricann Group Inc. (CSE:MARI)(FRANKFURT:75M)(OTCQB:MRRCF)(“Maricann” or the “Company”), is pleased to announce that the Company is now part of an...
Maricann Group Inc. is Awarded GMP Certification
April 30, 2018 00:15 ET
|
Maricann Group Inc.
TORONTO, April 30, 2018 (GLOBE NEWSWIRE) -- Maricann Group Inc. (CSE:MARI)(FRANKFURT:75M)(OTCQB:MRRCF)(“Maricann” or the “Company”), is pleased to announce that the Company is now part of an...
Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe
March 08, 2018 07:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...